NKTR Share Price Performance
US$68.43
58.01 (556.40%)
52.6% undervalued intrinsic discount
US$144.25
Fair Value
Price US$68.43
AnalystConsensusTarget US$144.25
AnalystHighTarget US$192.00
Fair ValueUS$144.25
Share Pricen/a
Narrative Update • May 18
Nektar Therapeutics Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
NKTR Community Narratives
AN
Fair Value
·Fair Value US$144.25 52.6% undervalued intrinsic discount
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value
·Fair Value US$192 64.4% undervalued intrinsic discount
Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles
Nektar Therapeutics is betting on a new immune-based treatment that could win over large groups of people with hard-to-treat skin and hair-loss conditions, helped by encouraging early results and a quicker review process. The upside comes with a big catch: years of heavy spending and slow approvals could keep the company burning cash and force tough funding choices.Read more
AN
US$192
64.4% undervalued intrinsic discount
Fair Value
Profit Margin
17.99%
Future PE
297.86x
Price in 2029
US$233.56
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
Key Takeaways Advancing innovative therapies like REZPEG in large, underserved markets could drive substantial revenue growth and improve long-term financial performance. Strong cash reserves and accelerated regulatory paths enable operational stability, support pipeline expansion, and reduce near-term financial risks.Read more
AN
US$144.25
52.6% undervalued intrinsic discount
Fair Value
Profit Margin
19.44%
Future PE
679.68x
Price in 2029
US$175.88
Trending Discussion
Recently Updated Narratives
AN
NKTR: Future Phase 3 Autoimmune Data Will Drive Upside Repricing Potential
Fair Value: US$192 64.4% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NKTR: Phase 3 Atopic Dermatitis And Alopecia Data Will Drive Future Upside
Fair Value: US$144.25 52.6% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nektar Therapeutics Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -4.69
- 100.00%
- -284.18%
- 10.5%
About NKTR
- Founded
- 1990
- Employees
- 63
- CEO
- WebsiteView website
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
